Results 221 to 230 of about 61,634 (258)

Dopamine agonists in schizophrenia: a review

European Neuropsychopharmacology, 1995
Although it is unlikely that the different types of course and severity of schizophrenia are caused by one neurochemical abnormality alone, indirect pharmacological evidence still suggests a relative excess of dopaminergic activity being implicated in the pathogenesis of most of the schizophrenic symptoms, e.g. positive symptomatology.
O, Benkert, F, Müller-Siecheneder, H, Wetzel   +2 more
openaire   +2 more sources

Partial dopamine agonists in schizophrenia

British Journal of Hospital Medicine, 2005
The emergence of partial dopamine agonists reinforces the argument for the dopamine hypothesis of schizophrenia. Aripiprazole (Abilify®) is the first of these compounds for the treatment of schizophrenia to be launched in the UK. Aripiprazole has a promising efficacy and favourable tolerability profile that suggests it has a significant role to play in
openaire   +2 more sources

Dopamine agonists and therapy compliance

Neurological Sciences, 2008
Dopamine replacement therapy in Parkinson's disease improves motor symptoms, however some patients suffer from motor and behavioural disturbances attributable to taking doses of medication well beyond the dose required to treat their motor disabilities.
openaire   +2 more sources

Dopamine agonists for cocaine dependence

2003
Cocaine is a major drug of abuse. Cocaine dependence is a common and serious condition, which has become nowadays a substantial public health problem. There is a wide and well documented range of consequences associated to chronic use of this drug, such as medical, psychological and social problems, including the spread of infectious diseases (e.g ...
B G O, Soares, M S, Lima, A A P, Reisser, M, Farrell   +3 more
openaire   +3 more sources

Clinical Pharmacology of Dopamine Agonists

Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2000
With the availability of newer dopamine agonists selective for dopamine (D 2 ) receptor subtypes, medical management of Parkinson's disease has progressed substantially. These agents can decrease the frequency of ergot‐related side effects and dyskinesias.
openaire   +2 more sources

Dopamine agonists

2007
Olivier, Rascol, Tarik, Slaoui, Wafa, Regragui, Fabiene, Ory-Magne, Christine, Brefel-Courbon, Jean-Louis, Montastruc   +5 more
openaire   +3 more sources

Dopamine agonists

Reactions Weekly, 2013
Valerie Suski, Mark Stacy
  +4 more sources

Dopamine agonists and hyperprolactinaemia

BMJ, 2009
Niamh M, Martin, Tricia, Tan, Karim, Meeran   +2 more
openaire   +2 more sources

Dopamine agonist withdrawal syndrome: A comprehensive review

Journal of the Neurological Sciences, 2017
Xin Xin Yu
exaly  

Dopamine supersensitivity psychosis and dopamine partial agonist: A retrospective survey of failure of switching to aripiprazole in schizophrenia

Journal of Psychopharmacology, 2015
Masayuki Takase, Nobuhisa Kanahara, Yasunori Oda   +2 more
exaly